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Although 5-aminolevulinic acid (ALA)-based photodynamic therapy (PDT) has proven to be clinically beneficial for the treatment of
certain cancers, including a variety of skin cancers, optimal tissue localisation still remains a problem. An approach to improve the
bioavailability of protoporphyrin IX (PpIX) is the use of ALA derivatives instead of ALA. In this work, we employed a subcutaneous
murine mammary adenocarcinoma to study the tissue distribution pattern of the ALA hexyl ester (He-ALA) in comparison with ALA
after their topical application in different vehicles. He-ALA induced porphyrin synthesis in the skin overlying the tumour (SOT), but it
did not reach the tumour tissue as efficiently. Only 5h after He-ALA lotion application, tumour porphyrin levels surpassed control
values. He-ALA delivered in cream induced a substantially lower porphyrin synthesis in SOT, reinforcing the importance of the vehicle
in the use of topical PDT. Porphyrin levels in internal organs remained almost within control values when He-ALA was employed.
The addition of DMSO to ALA formulation slightly increased tumour and SOT porphyrin biosynthesis, but it did not when added to
He-ALA lotion.
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Photodynamic therapy (PDT) of cancer is based on the adminis-
tration of a photosensitising compound with tumour-localising
properties, and subsequent irradiation with light of an appropriate
wavelength leading to selective damage to the treated tissue
(Henderson and Dougherty, 1992). The administration of 5-
aminolevulinic acid (ALA) to cells and tissues results in the
production of protoporphyrin IX (PpIX), through the haem
biosynthetic pathway, which can be clinically used as a photo-
sensitiser for both photodetection and also as a good alternative of
cancer PDT (Kennedy et al, 1990, 1996; Peng et al, 1997).
Although ALA-based PDT has proven to be clinically beneficial
for the treatment of certain cancers including a variety of skin
cancers, optimal tissue localisation is still a problem to be solved.
As ALA is a small molecule, it can penetrate through the skin and
into tumours after topical application. However, the clinical use of
PDT with ALA-induced PpIX is limited by different factors, such as
ALA diffusion through biological barriers, localisation of PpIX,
availability of oxygen and rapid photobleaching of PpIX (Van der
Akker et al, 2000a).
Since the skin and very likely the stratum corneum are the main
biological barriers limiting ALA diffusion, high ALA doses have to
be applied to produce sufficient PpIX levels suitable for PDT
(Cairnduff et al, 1994; Peng et al, 1995).
An approach to improve the bioavailability of PpIX is the use of
ALA derivatives instead of ALA as precursors for PpIX synthesis.
ALA esters, which are more lipophilic than ALA itself, are expected
to enhance its uptake, penetration and distribution. Several ALA
esters have been synthesised and tested in vitro in different cell
lines and it has been found that long-chained ALA esters were
more efficient than short-chained ones at improving PpIX
production in cells (Kloek and Beijersbergen van Henegouwen,
1996; Gaullier et al, 1997; Casas et al, 2001a).
5-Aminolevulinic acid hexyl ester (He-ALA) has proven to be
successful in inducing PpIX production and distribution in human
and porcine bladder mucosa ex vivo (Marti et al, 1999) and in
patients (Lange et al, 1999).
On the other hand, topical use of ALA esters was not found to be
better than ALA at increasing PpIX production, yet a surprisingly
high photosensitiser selectivity was achieved (Peng et al, 1996;
Casas et al, 2001b; Moan et al, 2001).
Another approach to optimise ALA penetration is the use of
enhancers. The results of experiments with penetration enhancers
and tape stripping indicate that the stratum corneum acts as a
barrier against ALA and He-ALA. The use of enhancers like
azacycloalkane derivatives augments PpIX production, especially
in the case of He-ALA (Van der Akker et al, 2000a).
Dimethylsulphoxide (DMSO), which also acts as a penetration
enhancer, among other amphiphilic molecules penetrates skin
well, probably because the electron-rich part of the molecule
has affinity for the aqueous layers of the stratum corneum
while the electron-poor portion prefers the lipid region (Wiechers,
1989).
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sIt has been shown that DMSO can increase the penetration of
various chemical agents through human skin (Stoughton and
Fritdch, 1964), although the mechanism is not yet known. It has
been reported that DMSO can improve the accumulation of PpIX
in cell lines (Malik et al, 1995). Employing ALA plus DMSO in vivo
in a transplantable murine adenocarcinoma, Casas et al (2000)
have found a higher porphyrin accumulation in the skin overlying
the tumour tissue and in the first 2mm of tumour.
The aim of this work was to improve the clinical application of
ALA PDT by studying the tissue distribution pattern of He-ALA
compared to ALA after their topical application in two different
vehicles in a subcutaneous murine mammary adenocarcinoma
implanted in mice. The effect of adding DMSO to the formulations
of both compounds was also evaluated.
MATERIALS AND METHODS
Animals
Male BALB/c mice 12 weeks old, weighing 20–25g, were used.
They were provided with food (Purina 3, Molinos Rı ´o de la Plata)
and water ad libitum. A suspension of 1.6510
5 cells of the LM2
cell line (Galli et al, 2000) derived from the murine mammary
adenocarcinoma M2 (Instituto Roffo, Buenos Aires) was sub-
cutaneously injected on the flanks of male BALB/c mice.
Experiments were performed at approximately day 20 after
implantation. Tumours of the same uniform size were employed
(1cm diameter). Animals received human care and were treated in
accordance with guidelines established by the Animal Care and
Use Committee of the Argentine Association of Specialists in
Laboratory Animals (AADEALC), in full accord with the UK
Guidelines for the Welfare of Animals in Experimental Neoplasia
(Workman et al, 1998).
Drugs
ALA was purchased from Sigma Chemical Co., St Louis, MO, USA.
ALA hexyl ester (He-ALA) was synthesised according to the
method previously described in Casas et al (1999a). All other
chemicals were of analytical grade.
ALA administration
The hydrochloric acid (HCl) salt of ALA and He-ALA were
dissolved in saline in a final volume of 0.2ml immediately before
use (lotion). The addition of 5% DMSO to this saline lotion
constituted the lotion/DMSO formulation. For the cream prepara-
tions, ALA and He-ALA were freshly dissolved in 50mg of an oil in
water emulsion cream (Genargen, Argentina).
Both ALA formulations were applied on the tumour, having
shaved the hair and rubbing with a smooth paintbrush for a period
of 5min, time at which no vestiges of either cream or lotion were
visible. Before any application, mice received mild anaesthesia
(Fentanyl and Diazepam). All formulations were applied under
occlusive dressing to avoid distribution of the compounds.
Tissue porphyrin extraction
After ALA or He-ALA topical application, animals were killed.
Before killing mice were injected with heparin (0.15ml, 1000UI),
and after killing they were perfused with 200ml of sterile saline.
The tissue samples were homogenised in a 4:1 solution of ethyl
acetate:glacial acetic acid mixture according to Batlle (1997).
Briefly, the mixtures were centrifuged for 30min at 3000g, and the
supernatants were added with an equal volume of 5% HCl.
Extraction with HCl was repeated until there was no detectable
fluorescence in the organic layer. The aqueous fraction was used
for the determination of porphyrins. For fluorometric determina-
tion, a Shimadzu RF-510 spectrofluorometer was used, with an
emission wavelength of 604nm and an excitation wavelength of
406nm, employing PpIX reference standard.
Statistical analysis
The unpaired t-test was used to establish the significance of
differences between groups. Differences were considered to be
statistically significant when Po0.05. Three mice per group were
employed.
RESULTS
Dose course of porphyrin levels after topical application of
ALA or He-ALA
The dose course of porphyrin levels in tumour, skin and
peritumoural skin is shown in Figure 1A–C. In tumour, after
application of ALA cream or lotion, porphyrin accumulation
increased with the amount of ALA applied, reaching a plateau at 5
and 15mg ALA, respectively. Highest porphyrin levels were found
when using ALA lotion with a peak of 1.7570.45mg porphyring
1
tissue at 15mg ALA. In general, employing the ALA lotion, values 3
times higher than either ALA cream or He-ALA were obtained.
When using He-ALA cream or lotion, porphyrin levels do not
increase significantly over control values.
The addition of 10% DMSO to ALA lotion increases the amount
of porphyrins formed in tumour from 15mg ALA onwards,
although values were not significantly much higher. When
employing 20mg ALA lotion or ALA lotion plus DMSO,
1.7570.25 and 2.570.5mg porphyring
1 tumour, respectively,
were accumulated. Instead, addition of DMSO to He-ALA lotion
did not enhance the amount of synthesised porphyrins.
In normal skin, ALA lotion also induced the synthesis of the
highest levels of porphyrin, reaching a plateau of 0.8370.13mgg
1
at 10mg ALA. Addition of DMSO to ALA lotion equalled lotion-
alone values within the 10–15mg ALA range, without increasing
further porphyrin levels. Again, porphyrins induced by He-ALA in
either lotion or cream were within control values.
In the skin overlying the tumour (SOT), plateaus were rapidly
reached within the 5–7.5mg range for both ALA and He-ALA, and
porphyrin values were alike for both compounds, independent of
the vehicle. ALA cream concentration higher than 15mg induced
significantly lower porphyrin levels compared to those reached at
the plateau (0.2970.04, Po0.05). Addition of DMSO to ALA lotion
showed a sharp peak at 15mg ALA (1.870.4mg porphyrinsg
1
tissue), but no further increase at other points as compared to ALA
lotion alone. Addition of DMSO to He-ALA lotion did not enhance
porphyrin synthesis but reduced it.
Figure 1D–F depicts porphyrin accumulation in liver, kidney
and spleen. In liver tissue, sharp peaks were obtained with 10mg
ALA in cream and lotion plus DMSO (6.270.85 and 4.170.25mg
porphyrinsg
1 tissue, respectively). Slight increases of porphyrin
levels were found after topical application of He-ALA and ALA
lotion, although they were not significantly different from the
control.
In kidney, maximum porphyrin accumulation was reached with
15mg ALA cream (3.270.3mg porphyrinsg
1 tissue). After
application of ALA lotion alone or plus DMSO, values doubled
controls. After He-ALA treatment porphyrins did not increase
significantly over the control in the range of doses studied,
independent of the vehicle.
In spleen, the highest levels of porphyrins were accumulated
after applying 10mg ALA cream and 15mg ALA lotion (3.270.5
and 3.970.5mg porphyring
1 tissue, respectively). Again, por-
phyrins were slightly increased over the control after He-ALA
treatment without significant changes in the range of doses
ALA and ALA hexyl ester on topical ALA-PDT
C Perotti et al
433
British Journal of Cancer (2003) 88(3), 432–437 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sstudied. Addition of DMSO to ALA did not enhance porphyrin
formation.
Tissue distribution of porphyrins after ALA or He-ALA
topical application
The pattern of porphyrin accumulation in lung, heart, ear, gut,
bladder and brain after application of different amounts of ALA in
cream or lotion is shown in Tables 1 and 2, respectively. When
using both ALA formulations, heart and gut showed a marked
increase in porphyrin levels. In addition to these tissues, some
enhanced porphyrin accumulation in a dose-dependent way after
ALA lotion application was found in ear and bladder. He-ALA
cream increases basal porphyrin levels in a dose-dependent way in
the heart (control 0.2970.03 vs 30mg He-ALA 0.5770.05mg
porphyring
1 tissue, Po0.05) and bladder (control 0.3670.03 vs
30mg He-ALA 0.8370.08mg porphyring
1 tissue, Po0.05), while
the other tissues remain within control values. On the other hand,
He-ALA lotion did not induce any change in basal porphyrin levels
for all the tissues studied (data not shown).
Time course of porphyrin levels after ALA or He-ALA
topical application
The time course of porphyrin levels after topical application of
ALA or He-ALA cream and lotion on tumour, skin and SOT is
shown in Figure 2A–C. Maximal accumulation was found in
tumour 3h after ALA application. He-ALA lotion induced an
increase slightly above control at 5h (very significant), but He-
ALA cream did not produce porphyrin synthesis.
In normal skin, ALA in both preparations induced a peak of
porphyrins at 8h. When using He-ALA in lotion, a defined peak
was observed at 5h but none in its cream formulation.
SOT exhibits a peak 3h after application of ALA lotion, whereas
ALA cream and both He-ALA formulations induced peaks at 8h.
In this tissue, levels obtained with He-ALA lotion were high and
equalled those obtained with ALA lotion.
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Figure 1 Porphyrin accumulation after topical application on the tumour and skin of various quantities of ALA or He-ALA. Different amounts of ALA
cream (J), ALA lotion (n), ALA lotion/DMSO (&), He-ALA cream (K), He-ALA lotion (m) and He-ALA lotion/DMSO (&) were applied on the
tumour. After 3h, tumour (A), skin (B), skin overlying the tumour (C), liver (D), kidney (E) and spleen (F) were excised and porphyrins were extracted as
detailed in the Materials and Methods. Each data point represents the average of three determinations. Error bars show standard deviations.
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sIn Figure 2D–F, liver, kidney and spleen time courses are
depicted. In these three tissues, ALA in either formulation induced
different peak times; instead porphyrin accumulation from He-
ALA did not change from basal porphyrin levels in any tissue.
DISCUSSION
The kinetics of ALA in lotion and cream formulations have already
been discussed in a previous work (Casas et al, 1999b). Here we
will focus on the differences between ALA and He-ALA topically
applied, also in lotion and cream vehicles.
From these results, we can conclude that He-ALA induces
porphyrin synthesis in the skin overlying the tumour but it cannot
reach the tumour tissue as efficiently. Only 5h after He-ALA lotion
application, tumour porphyrin levels surpass control values.
Porphyrins formed from He-ALA were more above controls in
remote skin tissue than in tumour tissue. Porphyrin concentration
in internal organs remained within control values when He-ALA
was employed.
Moreover, even in SOT, although He-ALA lotion-induced
synthesis equals ALA lotion, the amount of the ester needed is
1.5 higher than that of ALA. He-ALA delivered in cream induced a
substantially lower porphyrin synthesis than in saline, reinforcing
the importance of the vehicle in the use of topical PDT.
Moan et al (2001) studied the PpIX formation after topical
application of ALA, ALA methyl ester and He-ALA on normal skin
and on skin overlying a subcutaneous human colon adenocarci-
noma. By means of an in vivo fluorescence signal from SOT
measurements, they found that ALA induced the same levels of
PpIX as compared to He-ALA applied in a 20% cream formulation,
but in remote skin sites no fluorescence was detected. In our work,
we have also found that in SOT porphyrin levels induced by He-
ALA are equal to those obtained from ALA, and by means of
porphyrin extraction we have demonstrated that He-ALA does not
induce a significant amount of photosensitiser in the subcutaneous
tumour itself.
In accordance with our findings, Van den Akker et al (2000b)
demonstrated that the stratum corneum was the main barrier for
He-ALA penetration. They found that the ALA ester did not induce
higher PpIX production in normal mouse skin as compared to
ALA. Employing a cream formulation and tape stripping of the
stratum corneum, they demonstrated that this was the layer
limiting and lowering PpIX production.
Also Van den Akker et al (2000b), using hairless mice, showed
that ALA pentyl ester produces only slightly more PpIX than ALA
in UVB-induced (pre)cancerous skin lesions, while in normal skin,
porphyrin levels were equal from both ALA compounds. They
found higher PpIX levels in the stratum corneum of lesional skin,
but not in the dysplastic layer of the epidermis, showing that this
ester also poorly diffuses as compared to ALA. These lesions
consisted of actinic and seborrhoeic keratosis and squamous cell
carcinomas.
However, in a previous work (Casas et al, 2001b) we have
analysed porphyrin formation in chemically induced squamous
papillomas, after topical application of ALA and He-ALA in cream
and lotion formulations. Not only did we find porphyrin synthesis
from ALA in these highly keratinised papillomas, but we also
found porphyrin accumulation in internal organs, showing that the
ALA-hexyl ester does reach the dermis in this tumour model.
Moreover, after applying He-ALA in the normal skin of
nontumour-bearing mice, we also found the same pattern in
internal organs. Even in these hyperkeratotic papillomas, this
molecule diffuses freely. We could predict that He-ALA may be
highly useful, as it has already been proven with ALA methyl ester
(Fritsch et al, 1998) in the treatment of actinic keratosis and
verruca vulgaris.
In SOT, He-ALA peaks are delayed as compared to ALA lotion,
and this can be explained either by considering the additional step
of esterase breakage of the alcohol chain, difficulties in crossing
the stratum corneum. The fact that porphyrin biosynthesis induced
from ALA cream is also delayed, favours the latter hypothesis.
Moreover, culturing different tissue explants (tumour, normal
skin, SOT, liver, kidney and spleen) exposed to ALA or He-ALA,
we found that porphyrin levels from either compounds were
similar, supporting the proposal that there are no differences on
esterase activity for any tissue (Perotti et al, 2002).
The attempt to raise tumour porphyrin biosynthesis from He-
ALA by adding DMSO failed; on the contrary, the values obtained
were even lower. However, Van der Akker et al (2000a) found that
penetration enhancers like azacycloalkane derivatives augment
PpIX production from He-ALA. These differences may be ascribed
to different mechanisms of action for both compounds. Penetra-
tion enhancers such as DMSO exert a direct influence on the
Table 1 Tissue distribution of porphyrins after application of different amounts of ALA cream
Lung Heart Ear Gut Bladder Brain
Control 0.4970.08 0.2970.03 0.1570.05 0.3770.07 0.3670.03 0.1170.01
7.5mg ALA 0.5370.07 0.6570.06 0.2070.03 1.5370.23 0.5170.07 0.1170.05
15mg ALA 0.6070.09 1.8970.21 0.2170.05 1.7970.23 0.6370.03 0.1370.01
20mg ALA 0.4370.06 2.5370.15 0.1170.05 1.8370.26 0.5870.07 0.1870.02
30mg ALA 0.5070.07 2.8370.41 0.2070.05 2.1570.31 0.4070.06 0.1770.02
Different amounts of ala cream were topically applied on the tumour. Mice were killed 3h after drug administration and porphyrins (mgg
1 tissue) were determined
spectrophotometrically.
Table 2 Tissue distribution of porphyrins after application of different amounts of ALA in lotion
Lung Heart Ear Gut Bladder Brain
Control 0.4970.08 0.2970.03 0.1570.05 0.3770.07 0.3670.03 0.1170.05
7.5mg ALA 0.2870.05 1.4370.03 0.5870.06 1.1970.03 0.4070.04 0.1570.02
15mg ALA 0.3970.05 1.5370.21 0.8270.07 1.4170.12 0.5370.07 0.1770.03
20mg ALA 0.4570.03 1.9170.41 1.2470.10 1.4370.11 0.9370.06 0.1570.03
30mg ALA 0.5270.04 2.1370.33 1.4570.34 1.9770.25 0.8870.09 0.2070.04
Different amounts of ALA in lotion were topically applied on the tumour. Mice were killed 3h after drug administration and porphyrins (mgg
1 tissue) were determined
spectrophotometrically.
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saqueous regions between the polar lipid head groups of the bilayer,
altering the solubilising ability of this site, thereby promoting
partitioning into the skin. On the other hand, the nonpolar
enhancer Azone
s exerts its action on the hydrophobic tails of the
bilayer by upsetting their packing and increasing their fluidity
(Wiechers, 1989).
In conclusion, according to these results and those from Casas
et al (2001b) when compared to ALA, only superficial skin lesions
may be successfully treated with topical He-ALA PDT with the
advantage of tumour selectivity; instead malignancies such as chest
wall progression of breast cancer will probably fail this treatment.
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